Description
Anti-SLAMF7 Antibody, Non-Fucosylated (BioBet-025ZP) is a mouse monoclonal IgG1 antibody against SLAMF7. This product is an ADCC enhanced antibody produced by our Afuco™ platform.
Antibody Indication
Refractory Multiple Myeloma
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced SLAMF7 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
SLAMF7
Full Name
SLAM family member 7
Alternative Names
19A; CS1; CD319; CRACC
Gene ID
57823
UniProt ID
Q9NQ25
Cellular Localization
Membrane;Single-pass type I membrane protein
Involvement in Disease
Diseases associated with SLAMF7 include Smoldering Myeloma and Submandibular Gland Disease.
Related Pathways
Its related pathways are Innate Immune System and Class I MHC mediated antigen processing and presentation.
Function
1.Self-ligand receptor of the signaling lymphocyte activation molecule (SLAM) family. The SLAM receptor triggered by the homo- or heterotypic cell-cell interaction regulates the activation and differentiation of various immune cells, and therefore participates in the regulation and interconnection of innate immune response and adaptive immune response. Activity is controlled by the presence or absence of small cytoplasmic adaptor proteins SH2D1A/SAP and/or SH2D1B/EAT-2. Isoform 1 mediates NK cell activation through an erk-mediated pathway that is independent of sh2d1 extracellular signal regulation (PubMed: 11698418). By relying on the phosphorylated SH2D1B mechanism, it positively regulates the function of NK cells. The downstream signals involve PLCG1, PLCG2 and PI3K (PubMed: 16339536). In addition to the interaction between heterotypic NK cells and target cells, homotypic interactions between NK cells may also contribute to activation. However, in the absence of SH2D1B, NK cell function will be inhibited. It also has an inhibitory effect on T cells (similar). May be involved in lymphocyte adhesion (PubMed: 11802771). Monocytes activated by lipopolysaccharide negatively regulate the production of pro-inflammatory cytokines (PubMed: 23695528). 2.Isoform 3 does not mediate the activation of any NK cells.
Post-translational modifications
1.Glycosylation at Asn142, Asn148, Asn172, Asn176, Asn204, and Asn98 2.Modification sites at PhosphoSitePlus
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG1
Antibody Clone
BioBet-025ZP
Description
Elotuzumab is a humanized monoclonal antibody for relapsed multiple myeloma. Elotuzumab is produced in NS0 cells by recombinant DNA technology and targets SLAMF7. On November 30, 2015, Elotuzumab was approved by the US Food and Drug Administration.
Antibody Indication
Refractory Multiple Myeloma
Refractory Multiple Myeloma
